How Many Units Is a Microdose of Tirzepatide?

The question gets asked as though it has one answer: how many units is a microdose of tirzepatide? It does not, and the reason is worth more than the number. Tirzepatide is sold in four different presentations, and the same milligram dose sits in a different volume depending on which one you are holding. A unit count copied from a forum post is therefore not a conversion — it is a conversion for somebody else's device.

We'll do the arithmetic properly, from Lilly's own labels, and show where it breaks. What we will not do is tell you a microdose is proven, because it is not: no tirzepatide label defines a dose below 2.5 mg once weekly, and no randomized trial has tested one ¹.

The fact that makes most unit charts wrong

Both Mounjaro and Zepbound list the same four presentations in their prescribing information: pre-filled single-dose pens, single-dose vials, multi-dose vials, and single-patient-use KwikPens. The multi-dose vials and the KwikPen each contain four doses ^1,2.

Here is the part a units chart has to account for and usually cannot. The single-dose presentations deliver each dose in 0.5 mL. The multi-dose vial and the KwikPen deliver each dose in 0.6 mL ^1,2. Same milligrams, different volume — which means a different concentration, and therefore a different number on a syringe.

At the 2.5 mg starting dose, that works out to:

• •Single-dose pen or vial — 2.5 mg in 0.5 mL, which is 5 mg/mL. On a U-100 insulin syringe, 0.5 mL reads 50 units.
• •Multi-dose vial or KwikPen — 2.5 mg in 0.6 mL, stated on the label as 10 mg per 2.4 mL, which is 4.17 mg/mL. That same 2.5 mg reads 60 units ¹.

So the identical dose of the identical drug is 50 units in one presentation and 60 in another. A figure quoted as "a microdose of tirzepatide is X units" without naming the presentation is therefore right for two of the four containers and wrong for the other two — and nothing in the number itself tells you which.

Only one of the four can be measured at all

This is the second thing the question usually skips. Three of the four presentations are fixed-dose devices.

The pre-filled single-dose pen is one pen, one pre-set dose, no dial. There is nothing to count and nothing to adjust. You press and the full dose goes in.

The single-patient-use KwikPen holds four doses of a single strength — it is not a dial-a-dose device that offers a menu, it repeats the same fixed dose four times ¹. It is not a tool for delivering a fraction.

The single-dose vial is one dose in 0.5 mL, intended to be drawn and given in full.

The multi-dose vial is the only presentation where you draw your own volume from a stated concentration — and it is the only one where a units calculation is meaningful rather than improvised. That is not the same as the label endorsing a partial draw; the multi-dose vial exists to hold four full weekly doses, not to be divided into smaller ones.

The math, if you are going to do it anyway

If you are working from a compounded vial or the multi-dose presentation and you know the concentration, the calculation is simple division, and our microdose calculator runs it for you. Volume in milliliters equals your target dose in milligrams divided by the concentration in milligrams per milliliter. On a U-100 insulin syringe, one unit is 0.01 mL, so units equal milliliters multiplied by 100.

Worked at the label's own multi-dose concentration of 4.17 mg/mL, a hypothetical 0.5 mg dose is 0.12 mL, which is 12 units. At the single-dose concentration of 5 mg/mL, the same 0.5 mg is 0.1 mL — 10 units. Two units apart on a syringe barrel where two units is a fifth of the dose.

That gap is the whole argument for reading the concentration off the vial in front of you rather than trusting a chart. It is also why the compounded vials most microdosers actually use need their own check: compounded product is not required to match Lilly's concentrations at all, and we walk through measuring from an arbitrary one in how to reconstitute and measure a compounded GLP-1 microdose.

What the arithmetic cannot fix

Getting the units right is a measurement problem, and measurement problems have clean answers. The dose-response problem does not.

Tirzepatide's approved ladder starts at 2.5 mg once weekly, and that rung is explicitly a tolerance-building step rather than a maintenance dose ¹. The efficacy that made the drug famous came from the top of the ladder, not the bottom: in SURMOUNT-1, the phase 3 obesity trial, tirzepatide produced substantially greater weight reduction at its higher maintenance doses than at its lowest, across 72 weeks ³. A microdose sits below every dose that trial studied. Measuring 12 units perfectly does not move you onto that curve — it places you below the point where it was drawn. We cover the shape of that curve in GLP-1 dose-response: why lower doses do less, and what a low tirzepatide dose does and does not do in microdosing tirzepatide.

There is also a product risk that no amount of careful drawing removes. A pharmacovigilance analysis of compounded GLP-1 receptor agonists found markedly elevated reporting odds for preparation errors, contamination and compounding problems, alongside more reports of abdominal pain, gallbladder inflammation and hospitalization ⁴. The syringe is the accurate part of that chain. What is in the vial is the part you cannot verify at home, and it is discussed in is compounded GLP-1 safe?.

The short answer

There is no single unit count for a tirzepatide microdose, and any source that gives you one without asking which presentation you hold has already made an error. From the label: a 2.5 mg dose is 50 units from a single-dose pen or vial and 60 units from a multi-dose vial or KwikPen, because the volume per dose differs — 0.5 mL against 0.6 mL ^1,2. Three of the four presentations are fixed-dose devices you cannot meaningfully subdivide. Only the multi-dose vial, or a compounded vial of stated concentration, supports a real calculation, and even then the number depends entirely on the concentration printed on the container in front of you.

Do the division from your own vial, not from a chart. And talk to a clinician before dosing any GLP-1 below its labeled starting step — no label and no trial covers where you would be going.

For the wider picture, start with microdosing GLP-1: what the evidence actually shows. The equivalent question for the semaglutide devices is answered in how many units is a microdose in an Ozempic or Wegovy pen?, the dose ladder is mapped in our microdosing tirzepatide chart, and providers are compared in the GLP-1 microdose rankings hub.